Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03625349 · ClinicalTrials.gov registry record

Passive Limb Movement: A Tool to Assess Vascular Health and Guide Rehabilitation

A clinical trial of Aging and Cardiovascular Disease, sponsored by VA Office of Research and Development.

Active
Registry status
130
Enrollment target
1
Study location

NCT03625349 is a study of Aging and Cardiovascular Disease that is active but no longer recruiting, run by VA Office of Research and Development. The registered enrollment target is 130 participants, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03625349, a study of Aging and Cardiovascular Disease, is active but no longer recruiting, sponsored by VA Office of Research and Development.

ACTIVE NOT RECRUITING
Registry status
130 participants
Enrollment target
1
Study location

Study Summary

Brief Summary: Current U.S. Veteran demographics reveal an aging population with significant cardiovascular dysfunction. This ultimately manifests as mobility limitation, inactivity, and a subsequent worsening of cardiovascular disease (CVD) that often leads to death. However, despite this clear negative cycle of events, there is not a single clinically accepted, and therefore routinely utilized, method of assessing vascular health. As nitric oxide (NO) is anti-atherogenic and cardioprotective, identifying an in vivo bioassay of NO bioavailability has significant worth in this arena. Fueled predominantly by the VA Merit Award prior to this renewal application, single passive leg movement (sPLM) and the subsequent blood flow increase, measured non-invasively by ultrasound Doppler in the common femoral artery, is emerging as a method by which vascular endothelial function and therefore NO bioavailability can be determined. However, although this work has yielded an initial characterization of sPLM and established this method to be a novel, valid, and a clinically relevant approach to determine vascular health, further understanding of the sPLM response with advancing age and, ultimately, its implementation and assessment in both rehabilitation and clinical arenas is still necessary. With the growing interest in personalized medicine, the development of tools, such as sPLM, that allow individualized assessments to guide the physician, the patient, and the rehabilitative team, are essential. Therefore, two specific aims are proposed that will address the Central Hypothesis that the sPLM paradigm provides a clinically meaningful assessment of endothelial function. First, cardiac rehabilitation will be assessed by sPLM in the elderly, and, coupled with studies in the young, will elucidate the predominant pathways responsible for the change in endothelial function with aging and rehabilitation. Second, the CVD diagnostic value of the sPLM assessment of endothelial functio

Interventions

  • DRUG NG-Monomethyl-L-Arginine

Study Locations (1)

Utah

  • VA Salt Lake City Health Care System, Salt Lake City, UT - Salt Lake City

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2015-09-01
Est. Completion 2027-10-29

Sponsor

VA Office of Research and Development

1,668 total trials

What the Registry Record Tells You About NCT03625349

The ClinicalTrials.gov registry entry for NCT03625349 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (94% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Aging appearing as the primary indexed condition, and to 1 intervention - of which NG-Monomethyl-L-Arginine is the first listed.

NCT03625349 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.

Frequently Asked Questions

What is clinical trial NCT03625349 about?

NCT03625349 is a clinical study titled "Passive Limb Movement: A Tool to Assess Vascular Health and Guide Rehabilitation". Brief Summary: Current U.S. Veteran demographics reveal an aging population with significant cardiovascular dysfunction. This ultimately manifests as mobility limitation, inactivity, and a subsequent worsening of cardiovascular disease (CVD) that often leads to death. However, despite this clear ne...

What is the current status of trial NCT03625349?

This trial is currently active not recruiting. The enrollment target is 130 participants. The study started on 2015-09-01. Estimated completion is 2027-10-29.

What conditions does trial NCT03625349 study?

This clinical trial studies the following conditions: Aging, Cardiovascular Disease.

What interventions are being tested in trial NCT03625349?

The interventions under investigation include: NG-Monomethyl-L-Arginine (DRUG).

Who is sponsoring clinical trial NCT03625349?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03625349 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aging

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.